Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Prodrugs01:30

Prodrugs

Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A double-blind, randomized, multicenter, phase 2b study of the safety and efficacy of suvecaltamide in essential tremor.

Parkinsonism & related disorders·2026
Same author

Real-World Safety and Effectiveness of 24-Hour Foslevodopa/Foscarbidopa in Parkinson's Disease: ROSSINI Study 6-Month Interim Results.

Neurology and therapy·2026
Same author

Tavapadon as Adjunctive Treatment for Parkinson Disease: The TEMPO-3 Randomized Clinical Trial.

JAMA neurology·2026
Same author

DaxibotulinumtoxinA for Injection in Adults with Cervical Dystonia: Clinical Insights from a Real-World Early Experience Program.

Movement disorders clinical practice·2026
Same author

LRRK2 as a Potential Disease-Modifying Target in Sporadic Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2025
Same author

How to dose extended-release carbidopa-levodopa capsules (IPX203, CREXONT®) in patients with Parkinson's disease.

Clinical parkinsonism & related disorders·2025
Same journal

Combined Olfactory Testing and Substantia Nigra Hyperechogenicity for Diagnostic Differentiation of Parkinson's Disease.

European neurology·2026
Same journal

The Role of Stroke Severity in the Association between Hypoperfusion Intensity Ratio and Futile Reperfusion after Endovascular Treatment.

European neurology·2026
Same journal

The Parkinsonism of Salvador Dalí.

European neurology·2026
Same journal

Disorders of Arousal and Sleep-Related Hypermotor Epilepsy in Adults: A Challenging but Necessary and Critical Distinctive Diagnosis.

European neurology·2026
Same journal

Sex-Specific Phenotypic Characteristics in Obstructive Sleep Apnea: A Comprehensive Analysis of Anthropometric, Hematological, and Metabolic Profiles Stratified by Disease Severity.

European neurology·2026
Same journal

Historical and Clinical Analysis of a Case of Progressive Muscular Atrophy (1853-1871).

European neurology·2026
See all related articles

Related Experiment Video

Updated: Jun 23, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

Levodopa: past, present, and future.

Robert A Hauser1

  • 1Departments of Neurology, Molecular Pharmacology, and Physiology, University of South Florida, Tampa, FL 33606, USA. rhauser@health.usf.edu

European Neurology
|May 2, 2009
PubMed
Summary
This summary is machine-generated.

Levodopa remains a key Parkinson's disease treatment. New formulations aim for continuous drug delivery, potentially reducing motor fluctuations and side effects for better patient outcomes.

More Related Videos

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Related Experiment Videos

Last Updated: Jun 23, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Levodopa has been the primary treatment for Parkinson's disease (PD) for over four decades.
  • Optimizing levodopa delivery focuses on minimizing side effects, enhancing brain penetration, and stabilizing plasma levels.

Observation:

  • Current strategies involve combining levodopa with dopa decarboxylase (DDC) or catechol-O-methyltransferase (COMT) inhibitors.
  • These combinations aim to extend levodopa's effects and improve its availability in the central nervous system (CNS).

Findings:

  • Continuous dopaminergic stimulation, mimicking natural physiological patterns, may prevent or delay motor complications like 'wearing off' and dyskinesias.
  • Methods for continuous stimulation include oral levodopa/DDC inhibitor with COMT inhibitor combinations and enteral levodopa gel infusion.

Implications:

  • Ongoing research focuses on developing very long-acting oral and transdermal levodopa preparations.
  • These advancements promise more stable and effective Parkinson's disease management, potentially improving quality of life for patients.